Monastra Vincent J, Lynn Steven, Linden Michael, Lubar Joel F, Gruzelier John, LaVaque Theodore J
FPI Attention Disorders Clinic, Endicott, New York 13760, USA.
Appl Psychophysiol Biofeedback. 2005 Jun;30(2):95-114. doi: 10.1007/s10484-005-4305-x.
Historically, pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) have been considered to be the only type of interventions effective for reducing the core symptoms of this condition. However, during the past three decades, a series of case and controlled group studies examining the effects of EEG biofeedback have reported improved attention and behavioral control, increased cortical activation on quantitative electroencephalographic examination, and gains on tests of intelligence and academic achievement in response to this type of treatment. This review paper critically examines the empirical evidence, applying the efficacy guidelines jointly established by the Association for Applied Psychophysiology and Biofeedback (AAPB) and the International Society for Neuronal Regulation (ISNR). On the basis of these scientific principles, EEG biofeedback was determined to be "probably efficacious" for the treatment of ADHD. Although significant clinical improvement was reported in approximately 75% of the patients in each of the published research studies, additional randomized, controlled group studies are needed in order to provide a better estimate of the percentage of patients with ADHD who will demonstrate such gains in clinical practice.
从历史上看,注意力缺陷多动障碍(ADHD)的药物治疗一直被认为是减轻该病症核心症状的唯一有效干预措施。然而,在过去三十年中,一系列研究脑电图生物反馈效果的病例和对照组研究报告称,这种治疗方式能改善注意力和行为控制能力,在定量脑电图检查中增加皮质激活,并提高智力和学业成绩测试分数。这篇综述文章严格按照应用心理生理学和生物反馈协会(AAPB)与国际神经调节协会(ISNR)共同制定的疗效指南,对相关实证证据进行了审视。基于这些科学原则,脑电图生物反馈被判定对ADHD的治疗“可能有效”。尽管在每项已发表的研究中约75%的患者报告有显著临床改善,但仍需要更多随机对照组研究,以便更好地估计在临床实践中能有这种改善的ADHD患者比例。